Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820462 | 0.86 | EPHX1 (0.64) | GAAEPHX1TSHRCNR1SMN1; SMN2 | |
| SCHEMBL7569550 | 0.86 | EPHX1 (0.84) | GAAEPHX1TSHRCNR1SMN1; SMN2 | |
| SCHEMBL3897267 | 0.78 | SMN1; SMN2 (0.60) | GAAEPHX1TSHRCNR1SMN1; SMN2 | |
| SCHEMBL12196118 | 0.78 | EPHX1 (1.00) | GAAEPHX1TSHREPHX2ALDH1A1 | |
| SCHEMBL473628 | 0.77 | ALDH1A1 (0.54) | SMN1; SMN2LMNAALDH1A1CA12CA1 | |
| SCHEMBL473629 | 0.77 | ALDH1A1 (0.54) | SMN1; SMN2LMNAALDH1A1CA12CA1 | |
| SCHEMBL20356557 | 0.74 | LMNA (0.54) | GAAEPHX1TSHRCNR1SMN1; SMN2 | |
| SCHEMBL14647564 | 0.73 | EPHX1 (0.48) | GAAEPHX1TSHRCNR1SMN1; SMN2 | |
| SCHEMBL12820457 | 0.72 | EPHX1 (0.50) | GAAEPHX1CNR1EPHX2ALDH1A1 | |
| SCHEMBL1514666 | 0.72 | GAA (0.57) | GAAEPHX1TSHRCNR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | GAA 3043/4885EPHX1 3828/4885TSHR 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.